INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SKIN
SUSTAINABILITY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
MEDIA PACK
CONTRIBUTE
Subscribe
INJECTION
DUAL CHAMBER
FORMULATION
PFS
WEARABLES
ALL INJECTION
OCULAR
ORAL
RESPIRATORY
PULMONARY
NASAL
ALL RESPIRATORY
SKIN
SUSTAINABILITY
MORE
INTERVIEWS
EXPERT VIEWS
EARLY INSIGHTS
COMPANY LISTINGS
OUR AUTHORS
THE MAGAZINE
EVENTS
ED CALENDAR
MEDIA PACK
CONTRIBUTE
SEARCH
SEARCH
advanced search
EXPERT VIEW
EXPERT VIEW
Catriona Eldridge
PHARMACEUTICAL INDUSTRY SUSTAINABILITY TARGETS, ONE YEAR ON
Catriona Eldridge, analyses whether the pharmaceutical industry is meeting its targets and doing enough in the fight against climate change.
EXPERT VIEW
Alastair Willoughby
REUSABLE VERSUS SINGLE-USE DEVICES: TRADE-OFFS IN IMPROVING SUSTAINABILITY
Alastair Willoughby and Prem-Sagar Tank, explore various device trade-offs for both sustainability and cost in reusable injection devices, and consider how this compares with single-use devices.
EXPERT VIEW
Matt Parker
SCALING GLP-1 DRUGS WITHOUT A MOUNTAIN OF WASTE
Matt Parker, Simon Lyons and Alex Lyness, look at how the continued success of glucagon-like peptide-1 drugs is bringing into focus the need for environmentally sustainable self-injection systems. They discuss whether reloadable autoinjectors could be the way to boost sustainability, lower cost per dose, and match the scale and rate of adoption of these new therapies.
EXPERT VIEW
Dr Zaid Aqrawe
Merxin Ltd
SOFT MIST INHALERS VERSUS NEBULISERS: DELIVERY EQUIVALENCE & FUTURE THERAPIES
Zaid Aqrawe, Philippe Rogueda, Darragh Murnane and Bryan Eng, discuss the opportunity presented by soft mist inhalers as an alternative delivery device to nebulisers for inhaled therapies, contrasting the two device categories across multiple factors.
EXPERT VIEW
Dr Ethan Miller
BUBBLE-WRAPPED REMEDIES: HOW LIPID-ENCASED THERAPEUTICS COULD TRANSFORM INHALATION
Ethan Miller and Heather Jameson shed light on some of the intricacies that lipid-encapsulated therapeutics bring to the realm of inhalation therapies, and some considerations on how the type of inhalation device selected may help to mitigate issues around formulation stability and efficient delivery to target cells.
EXPERT VIEW
Dr Nia Stevens
HOW TO CHOOSE THE RIGHT INTRANASAL VACCINE DEVICE
Nia Stevens, discusses the potential benefits of developing vaccines for intranasal administration with a suitable drug delivery device, as well as the challenges associated with this delivery route.
EXPERT VIEW
Eric Kaneps
THE PATH TO NASAL DRUG PRODUCT COMMERCIALISATION
Eric Kaneps discusses the benefits of nasal drug delivery compared with other administration routes – and the challenges in R&D and clinical manufacturing.
EXPERT VIEW
Dr Carolina Dantas
EXPLORING THE POTENTIAL OF NEBULISED BIOLOGICS
Carolina Dantas and Ulf Krueger consider the challenges when it comes to the successful delivery of inhaled biological drugs.
EXPERT VIEW
Tom Oakley
Sanner Group
DRUG DELIVERY TRENDS FOR 2024
Tom Oakley and Kamaal de Silva consider how keeping abreast of the latest trends can help the industry predict and prepare for the future and, commenting from Springboard's privileged position at the centre of many of the drug delivery sector’s most exciting developments, discuss the top trends to look out for in 2024.
EXPERT VIEW
Kamaal de Silva
FROM CONCEPT TO CURE: MASTERING LIQUID SILICONE RUBBER FOR MEDICAL DEVICE DESIGN
Kamaal de Silva discusses the potential value of liquid silicone rubber in medical device design, including how its processing differs from other elastomers and how the challenges involved in its design and implementation can be overcome with specialist knowledge and experience.
EXPERT VIEW
Paul Draper
UNLOCKING THE POTENTIAL OF CONNECTED DRUG DELIVERY DEVICES FOR DIABETES
Paul Draper discusses the current state of connected injection pens and devices in the diabetes space, exploring the benefits that connectivity can bring to drug delivery devices and considering how to exemplify good design in a connected injection device for diabetes drug therapies.
EXPERT VIEW
Ross Errington
FUTURE-PROOFING pMDI DESIGN TO FIT A CHANGING MARKET
Ross Errington explores how pharmaceutical companies can evolve their pMDI drug products to make them fit for the future considering the several recent regulatory changes that are transforming the landscape of inhalation drugs.
EXPERT VIEW
Finn Heraghty
THE END OF THE ROAD FOR pMDIs?
Finn Heraghty and Heather Jameson explore the extent to which the healthcare needs of a population could be covered by the combined use of soft mist inhalers and dry powder inhalers, and discuss the factors that will impact the continued importance of pressurised metered dose inhalers going forward.
EXPERT VIEW
Dr Mark Allen
TAKING A DRUG TO FIRST-IN-HUMAN TRIALS IN A BESPOKE DEVICE FOR TARGETED INTRANASAL DELIVERY
Mark Allen, Andrew Fiorini and Shai Assia discuss the need to develop delivery devices early when formulating nasally delivered drugs for systemic and local action, and a method by which the route to clinic can be made easier, faster and cheaper.
EXPERT VIEW
Dr Richard Johnson
NASAL DRUG DELIVERY: OVERCOMING CHALLENGES WITH A ROBUST PLATFORM STRATEGY
Richard Johnson explores the changing nasal delivery landscape, highlighting challenges in nasal drug formulation and potential methods to overcome them.
EXPERT VIEW
Dr Carolina Dantas
THE IMPORTANCE OF THE BREATHING MANOEUVRE IN NEBULISED THERAPIES
Carolina Dantas and Ulf Krueger highlight the importance of the breathing manoeuvre in nebulised therapies – and describe a small study designed to test the effectiveness of patient feedback technology when it comes to guiding the inhalation manoeuvre.
EXPERT VIEW
Michael Astle
TRANSFORMING PHARMA MANUFACTURING TO DRIVE SUSTAINABILITY AND COST EFFICIENCY
Michael Astle, Gareth Jenkins and Edward Mayo explore current strategies to reduce carbon emissions and drive cost efficiency throughout the healthcare industry.
EXPERT VIEW
Will Morris
ENVIRONMENTAL DRIVERS FOR CHANGE IN DRUG DELIVERY DEVICES
Will Morris discusses the positive changes that have occurred when it comes to environmental sustainability in the medical industry, in the context of examining what more can be done.
EXPERT VIEW
Jimin Han
SHAPING A SUSTAINABLE BIOPHARMA INDUSTRY
Jimin Han delves into the intricate landscape of sustainability challenges within the biopharma industry and explores the innovative solutions that are steering drug development toward a greener future.
EXPERT VIEW
Paramesh Natarajan
HOW LIFECYCLE ASSESSMENT SUPPORTS INSIGHT-DRIVEN SUSTAINABLE DESIGN
Paramesh Natarajan, Shadi Bavar and Charlie Dean present the case for using screening lifecycle assessments to lead into more detailed targeted and comprehensive lifecycle assessments focused on the areas of greatest environmental impact, using a screening lifecycle assessment of a hypothetical body-worn injector as an example.
EXPERT VIEW
Tom Oakley
“A CHILD IS NOT A SMALL ADULT”: CHALLENGES AND SOLUTIONS IN DEVELOPING DRUG DELIVERY DEVICES FOR CHILDREN
Tom Oakley and Heather Jameson consider the main differences in developing therapies and drug delivery devices for children and babies when compared with adults.
EXPERT VIEW
David DeSalvo
IDENTIFYING AND OVERCOMING THE CHALLENGES OF INJECTABLE COMBINATION PRODUCT EVOLUTION
David DeSalvo considers some potential challenges that the rapid evolution of autoinjectors (and combination product injectables in general) raises, along with how the industry can successfully address this cycle of reinvention.
EXPERT VIEW
Roger Bohannan
INJECTING INNOVATIVE SOLUTIONS INTO CONNECTED DELIVERY DEVICES
Roger Bohannan discusses the capabilities and design challenges of connected drug delivery devices.
EXPERT VIEW
Dave Beckstoffer
INCORPORATING MOTION DESIGN AT EARLY STAGES OF WEARABLE INJECTOR DEVELOPMENT
Dave Beckstoffer discusses the often overlooked importance of including motion system design considerations from the very earliest stages of wearable injector development, and how doing so can reduce costs, shorten timelines and improve patient outcomes.
Prev
1
…
3
4
5
6
7
…
15
Next
Top
